A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)

Conclusions This study does not support any clinically meaningful benefit or harm of mesalazine compared with placebo in unselected patients with IBS-D. More precise subtyping based on underlying disease mechanisms is needed to allow more effective targeting of treatment in IBS. Trial registration number NCT01316718.

http://gut.bmj.com/cgi/content/short/65/1/91?rss=1

Source: Gut - December 8, 2015 Category: Gastroenterology Authors: Lam, C., Tan, W., Leighton, M., Hastings, M., Lingaya, M., Falcone, Y., Zhou, X., Xu, L., Whorwell, P., Walls, A. F., Zaitoun, A., Montgomery, A., Spiller, R. Tags: Diarrhoea, Open access Neurogastroenterology Source Type: research